Silence Therapeutics (NASDAQ:SLN) Shares Gap Up – Still a Buy?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $11.95, but opened at $16.70. Silence Therapeutics shares last traded at $16.7930, with a volume of 7,146,276 shares.

Key Headlines Impacting Silence Therapeutics

Here are the key news stories impacting Silence Therapeutics this week:

• Positive Sentiment: Strong Phase 2 SANRECO results fueled optimism. Divesiran met the trial’s primary and secondary endpoints in 48 phlebotomy-dependent patients with polycythemia vera. The results support the therapy’s potential best-in-class profile and appear to be the main reason SLN shares have moved higher recently. Positive SANRECO Phase 2 trial results
• Positive Sentiment: Analyst sentiment remains favorable. Silence Therapeutics received a consensus rating of “Moderate Buy,” which may provide additional support following the clinical readout. Silence Therapeutics analyst consensus rating
• Neutral Sentiment: Short-interest data provides no usable signal. The reported figures show zero shares sold short both currently and on the prior reporting date, with a zero-day days-to-cover ratio. The stated percentage increase is not meaningful because the underlying figures are zero.
• Negative Sentiment: Silence announced a proposed $150 million ADS offering. The financing could strengthen the balance sheet and fund development of divesiran, but issuing new American Depositary Shares would dilute existing shareholders and may pressure the stock in the near term. $150 million ADS offering
• Negative Sentiment: Quarterly losses exceeded expectations. The company reported a loss of $0.26 per share versus the $0.14 consensus loss. Silence remains an unprofitable clinical-stage biotechnology company, adding financial risk despite the encouraging trial data. Second-quarter 2026 financial results

Analysts Set New Price Targets

SLN has been the topic of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, June 17th. Cantor Fitzgerald started coverage on Silence Therapeutics in a research report on Wednesday, June 24th. They issued an “overweight” rating for the company. Finally, Morgan Stanley lifted their price target on Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Silence Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $53.50.

Silence Therapeutics Trading Down 4.9%

The company’s 50-day simple moving average is $9.66 and its 200-day simple moving average is $7.31. The stock has a market capitalization of $693.01 million, a price-to-earnings ratio of -11.46 and a beta of 1.39.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 96.82% and a negative net margin of 8,943.86%.The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $1.13 million. On average, equities research analysts expect that Silence Therapeutics PLC Sponsored ADR will post -1.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP acquired a new position in shares of Silence Therapeutics in the fourth quarter worth approximately $897,000. ADAR1 Capital Management LLC raised its holdings in Silence Therapeutics by 628.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock worth $907,000 after purchasing an additional 148,514 shares during the last quarter. Ishara Investments LP acquired a new position in shares of Silence Therapeutics in the 4th quarter worth approximately $1,459,000. SG Americas Securities LLC lifted its position in shares of Silence Therapeutics by 11.8% in the 1st quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock worth $1,511,000 after purchasing an additional 30,358 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Silence Therapeutics by 65.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after purchasing an additional 5,421 shares during the last quarter. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.